| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4449 | Ro 31-8220 | Potent protein kinase C (PKC) inhibitor |
|
| DCC4450 | Ro 32-7315 | ADAM17-selective inhibitor |
|
| DCC4451 | Ro 48-8587 | Competitive AMPA receptor antagonist |
|
| DCC4452 | Ro 64-5229 | Selective, non-competitive Metabotropic_glutamate_receptor>mGlu2 antagonist |
|
| DCC4453 | Ro 8-4304 | Novel NR2B selective, non-competitive, voltage-independent antagonist |
|
| DCC4454 | Ro 8-4304 Hydrochloride | NMDA receptor antagonist , specifically suppressing the severe autoimmune phenotypes of chs3-2D (chilling sensitive 3, 2D), including the arrested growth morphology and heightened PR (Pathogenesis Related) gene expression |
|
| DCC4455 | Ro-09-4609 | Potent and selective Candida albicans N-myristoyltransferase (CaNmt) inhibitor |
|
| DCC4456 | Ro-09-4879 | Potent and selective Candida albicans N-myristoyltransferase (CaNmt) inhibitor, exhibiting antifungal activity in vivo |
|
| DCC4457 | Ro-23-7553 | Vitamin D analogue, showing significant in vitro and in vivo antitumor activity. |
|
| DCC4458 | Ro26-4550 Tfa Salt | Novel reversible inhibitor of interleukin-2 (IL-2) |
|
| DCC4459 | Ro31-4724 | Dual inhibitor of HDAC and MMP |
|
| DCC4460 | ro3206145 | Potent and selective inhibitor of the p38 MAPK catalytic domain |
|
| DCC4461 | Ro-363 | Beta(1) adrenoceptor-selective agonist |
|
| DCC4462 | Ro4432717 | Novel mGlu2/3 negative allosteric modulator (NAM) |
|
| DCC4463 | Ro4491533 | Selective negative allosteric modulator of mGlu3 |
|
| DCC4464 | Ro4583298 | Novel highly potent dual NK1/NK3 receptor antagonist |
|
| DCC4465 | Ro4597014 | Novel Glucokinase Activator for the Treatment of Type 2 Diabetes |
|
| DCC4466 | Ro5234444 | Orally active chemokine receptor CCR2 antagonist preventing glomerulosclerosis and renal failure in type 2 diabetes |
|
| DCC4467 | Ro5527239 | Novel potent, orally available GPBAR1 agonist |
|
| DCC4468 | Ro-57-bpyne | Novel γ-secretase modulator photoaffinity probe, identifying distinct allosteric binding sites on presenilin that can be exploited to reduce levels of pathogenic Aβ species |
|
| DCC4469 | Ro6800020 | Potent γ-secretase modulator (GSM) |
|
| DCC4470 | Ro6842262 | Novel potent and selectve LPA1 antagonist, attenuating NHLF human lung fibroblast cell proliferation and contraction in vitro, reducing plasma histamine levels in mouse LPA-challenge model |
|
| DCC4471 | Ro7101556 | Novel potent γ-secretase modulator (GSM) with high solubility, balanced lipophilicity, and showing no phototoxicity and PIK4CB side bing activity |
|
| DCC4472 | Robalzotan | Selective antagonist at the 5-HT1A receptor |
|
| DCC4473 | Rocepafant | Platelet-activating factor (PAF-R) antagonist, selectively for intracellular PAF binding sites |
|
| DCC4474 | Rockii-in-di | Novel potent competitive inhibitor of Rho-associated coiled-coil-containing protein kinase 2 (ROCKII) |
|
| DCC4475 | Rock-in-(r)14f | Novel potent ROCK inhibitor |
|
| DCC4476 | Rock-in-32 | Potent Rho--kinase (ROCK) inhibitor |
|
| DCC4477 | Rock-in-d1 | Novel potent and selective ROCK inhibitor |
|
| DCC4478 | Rock-in-d2 | Novel potent and selective ROCK inhibitor |
|
